Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Hanley

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
The Journal of Infectious Diseases|February 13, 2024
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral TherapyCynthia L Gay, Patrick J Hanley, Shane D Falcinelli, et al.
Blood Advances|March 4, 2022
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMTHannah Kinoshita, Kenneth R Cooke, Melanie Grant, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Nature Medicine|July 1, 2026
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trialStephanie Gomez, Rachel A DiCioccio, Ashley E Geiger, et al.
The Journal of Allergy and Clinical Immunology|February 28, 2016
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesSwati Naik, Sarah K Nicholas, Caridad A Martinez, et al.
Nature Communications|May 15, 2025
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 studyDanielle K Sohai, Michael D Keller, Patrick J Hanley, et al.
Blood|December 17, 2020
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane proteinMichael D Keller, Katherine M Harris, Mariah A Jensen-Wachspress, et al.
Nature Communications|April 18, 2024
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessmentMichael D Keller, Patrick J Hanley, Yueh-Yun Chi, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
The Journal of Infectious Diseases|February 13, 2024
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral TherapyCynthia L Gay, Patrick J Hanley, Shane D Falcinelli, et al.
Blood Advances|March 4, 2022
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMTHannah Kinoshita, Kenneth R Cooke, Melanie Grant, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Nature Medicine|July 1, 2026
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trialStephanie Gomez, Rachel A DiCioccio, Ashley E Geiger, et al.
The Journal of Allergy and Clinical Immunology|February 28, 2016
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesSwati Naik, Sarah K Nicholas, Caridad A Martinez, et al.
Nature Communications|May 15, 2025
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 studyDanielle K Sohai, Michael D Keller, Patrick J Hanley, et al.
Blood|December 17, 2020
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane proteinMichael D Keller, Katherine M Harris, Mariah A Jensen-Wachspress, et al.
Nature Communications|April 18, 2024
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessmentMichael D Keller, Patrick J Hanley, Yueh-Yun Chi, et al.
Pageof 10